Compare AbCellera Biologics Inc (ABCL) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Bath & Body Works Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Bath & Body Works Inc trades at $19.46 (market cap $4.16B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 3.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BBWI | |
|---|---|---|
Market Cap | $2.35B | $4.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $33.65 |
52-Week Low | $2.78 | $14.85 |
Enterprise Value | $1.99B | $8.05B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BBWI trades at $20.62, down 6.1% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock is valued attractively with a P/E of 6.23 and P/S of 0.62, while recent earnings beat expectations in Q1 2026. Revenue has declined over five years, but the company maintains strong cash flow and a new partnership with Ulta Beauty aims to expand reach.
The outlook is mixed: deep valuation discounts and strategic initiatives like the Ulta partnership offer upside, but persistent revenue declines and high debt pose risks. Analyst consensus is a $22.50 price target with no sell ratings, indicating cautious optimism for a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
